Company: SXTPW
Filing Date: 2025-06-06
Form Type: DRS
Source: 0001213900-25-052232
Chunk: 51

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-06-06
Form: DRS
Chunk 51
---
 as of March 31, 2025, and excludes:                                                                 |

| ● | 57,068                                                                   
 shares of common stock reserved for future issuance under the 2022 Plan; |

| ● | 2,127,070                                                                                                                       
 shares of common stock issuable upon exercise of outstanding warrants at a weighted average exercise price of $15.85 per share; |

| ● | 137,637 shares of common                                                                                          
 stock issuable upon exercise of outstanding options at a weighted average exercise price of $13.92 per share; and |

| ● | shares                                                                                     
 of common stock issuable upon the conversion of 76,480 shares of Series A Preferred Stock. |

<div align='center'>26

DILUTION</div>

Purchasers of our securities in this offering
will experience an immediate and substantial dilution in the net tangible book value of their shares of our common stock. Dilution in
net tangible book value represents the difference between the public offering price per share of our common stock and the as adjusted
net tangible book value per share of our common stock immediately after the offering.

The historical net tangible book value of our
common stock as of March 31, 2025 was $3,879,104 or $2.63 per share. Historical net tangible book value per share of our common stock represents
our total tangible assets (total assets less intangible assets) less total liabilities divided by the number of shares of our common stock
outstanding as of that date.

After giving effect to the sale of up to shares
of common stock, or in lieu thereof, Pre-Funded Warrants to purchase up to
shares of common stock, and accompanying Series A-1 Warrants to purchase up to shares
of common stock and Series A-2 Warrants to purchase up to shares
of common stock at an assumed public offering price per share of common stock or Pre-Funded Warrant and accompanying Warrants of $ ,
which is equal to the last reported sale price of our common stock on The Nasdaq Capital Market on ,
2025, assuming exercise in full of any Pre-Funded Warrants offered in this offering, and after deducting the estimated placement agent
fees and estimated offering expenses payable by us, and excluding the proceeds, if any, from the exercise of the Warrants issued in this
offering, our as adjusted net tangible book value as of March 31, 2025 would have been approximately $
million, or approximately $ per share. This